Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15869590 | 0.84 | CLCN2 (0.38) | MAPTTP53HDAC8ALDH1A1GAA | |
| SCHEMBL1290914 | 0.84 | BAZ2B (0.38) | MAPTEPHB3TP53HDAC8ALDH1A1 | |
| SCHEMBL15670600 | 0.80 | MAPT (0.36) | MAPTTP53HDAC8ALDH1A1GAA | |
| SCHEMBL1290844 | 0.77 | EGLN1 (0.42) | MAPTTP53HDAC8ALDH1A1 | |
| SCHEMBL25395169 | 0.74 | HDAC8 (0.50) | MAPTEPHB3HDAC8ALDH1A1GAA | |
| SCHEMBL1290630 | 0.74 | PRMT5 (0.36) | MAPTEPHB3HDAC8ALDH1A1GAA | |
| SCHEMBL2498109 | 0.74 | ALDH1A1 (0.51) | MAPTTP53HDAC8ALDH1A1GAA | |
| SCHEMBL8607290 | 0.72 | ALDH1A1 (0.40) | ACP3MAPTPGK1PGK2ALDH1A1 | |
| SCHEMBL8607018 | 0.72 | ATP4A (0.30) | — | |
| SCHEMBL24857446 | 0.71 | ALDH1A1 (0.36) | MAPTHDAC8ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | claimed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | claimed |
| US-5716964-A | BRAIN DISORDERS; ANTIISCHEMIC AGENTS | G.D. SEARLE & CO. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5633237-A | Imidazo[1,2-a]pyridinylalkyl phosphonic acid compounds for treatment of neurotoxic injury | G.D. SEARLE & CO. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5360796-A | Treatment of hypoxia, anoxia or ischemia | G. D. SEARLE & CO. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |